Qinlock (ripretinib) — United Healthcare
Gastrointestinal stromal tumor (GIST)
Preferred products
- imatinib (Gleevec)
- sunitinib (Sutent)
- regorafenib (Stivarga)
- Ayvakit (avapritinib)
- dasatinib (Sprycel)
Initial criteria
- Diagnosis of gastrointestinal stromal tumor (GIST)
- AND one of the following: gross residual disease (R2 resection) OR unresectable primary disease OR tumor rupture OR recurrent/metastatic
- AND one of the following: (a) History of progression on imatinib (Gleevec), sunitinib (Sutent), and regorafenib (Stivarga) OR (b) History of progression on imatinib (Gleevec) AND history of intolerance to sunitinib (Sutent) OR (c) PDGFRA exon 18 mutations that are insensitive to imatinib (including PDGFRA D842V) AND history of progression on Ayvakit (avapritinib) AND history of progression on dasatinib (Sprycel)
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Qinlock therapy
Approval duration
12 months